ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Adjuvanted RSVPreF3 vaccine

Its studies are mostly in Cardiovascular Diseases · Respiratory Syncytial Virus Infections, led by GlaxoSmithKline.

Furthest: phase 2, since Jul 23, 20252 company-led studies, 2 open or runningNext primary completion: Jan 12, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline22 open or runningphase 2since Jul 23, 2025Jul 23, 2025Jan 12, 2027phase 2 · NCT07092865

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2025First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT07092865 · 168 enrolled · United States, Australia, Canada and more
  2. Jul 14, 2026Phase 2 study in Cardiovascular DiseasesNCT07712380 · 450 planned

Ahead

  1. Jan 12, 2027Primary completion: phase 2 study in Respiratory Syncytial Virus InfectionsNCT07092865
  2. May 2, 2029Primary completion: phase 2 study in Cardiovascular DiseasesNCT07712380

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Adjuvanted RSVPreF3 vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07712380Cardiovascular Diseases2Not yet recruitingMay 2, 2029450
NCT07092865Respiratory Syncytial Virus Infections · United States, Australia, Canada and more2Active, not recruitingJan 12, 2027168

How it is read

Names in the registry

  • “Adjuvanted RSVPreF3 vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.